Using BK degradation for measuring the protease (CPN and ACE) activity in patients’ sera, we noted a general reduction in the BK degradation capacity in hospitalized COVID-19 patients, but also in some convalescent patients. This evidence concerns the gene CPN1 and COVID-19.